文献速递冠心病血脂与心血管预防

急性冠脉综合征后阿利西尤单抗达标LDL-C水平的疗效与安全性:ODYSSEY OUTCOMES倾向评分匹配分析

Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial.
PubMed 文献 · Circulation · 2021-01-13

该研究对ODYSSEY OUTCOMES试验中18 924例近期急性冠脉综合征患者进行倾向评分匹配分析,按阿利西尤单抗治疗4个月时LDL-C达标水平分层(<25、25-50、>50 mg/dL),比较各组主要不良心血管事件。匹配后,LDL-C<25 mg/dL与25-50 mg/dL组的事件风险降低相似(HR均为0.74),>50 mg/dL组获益较少(HR 0.87,95%CI 0.73-1.04)。未发现LDL-C<15 mg/dL的短期安全性问题。

要点

  • 阿利西尤单抗达标LDL-C<25 mg/dL与25-50 mg/dL的心血管获益相似。
  • 达标LDL-C>50 mg/dL与依从性差相关且获益较少。
  • 短期LDL-C<15 mg/dL未观察到安全性问题。

核心结论

  • 在调整基线特征和依从性差异后,阿利西尤单抗治疗达标LDL-C<25 mg/dL与25-50 mg/dL的患者MACE风险降低相似。

研究设计与样本

  • 对ODYSSEY OUTCOMES试验中18 924例近期急性冠脉综合征且接受强化或最大耐受他汀治疗的患者进行倾向评分匹配分析。
  • 阿利西尤单抗组按治疗4个月时LDL-C达标水平分为<25 mg/dL(n=3357)、25-50 mg/dL(n=3692)和>50 mg/dL(n=2197)三层,每层与安慰剂组按1:1倾向评分匹配后比较第4个月后的MACE。

主要发现

  • 匹配后,LDL-C<25 mg/dL组MACE风险HR为0.74(95%CI 0.62-0.89),绝对风险降低0.92例/100患者年。
  • LDL-C 25-50 mg/dL组MACE风险HR为0.74(95%CI 0.64-0.87),绝对风险降低1.05例/100患者年。
  • LDL-C>50 mg/dL组依从性较差且获益较少,MACE风险HR为0.87(95%CI 0.73-1.04),绝对风险降低0.62例/100患者年。
  • 未发现与短期LDL-C<15 mg/dL相关的安全性问题。

临床怎么用

  • 对于近期急性冠脉综合征患者,使用阿利西尤单抗将LDL-C降至<25 mg/dL或25-50 mg/dL均可带来相似的MACE风险降低。

局限性

  • 本研究为ODYSSEY OUTCOMES试验的倾向评分匹配分析,非随机对照分层比较,可能存在未测量混杂。
  • LDL-C>50 mg/dL组患者依从性较差,可能影响该组获益评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recent international guidelines have lowered recommended target levels of low-density lipoprotein cholesterol (LDL-C) for patients at very high risk for major adverse cardiovascular events (MACE). However, uncertainty persists whether additional benefit results from achieved LDL-C levels below the conventional targets. Inferences from previous analyses are limited because patients who achieve lower versus higher LDL-C on lipid-lowering therapy differ in other characteristics prognostic for MACE and because few achieved very low LDL-C levels. To overcome these limitations, we performed a propensity score-matching analysis of the ODYSSEY OUTCOMES trial (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) which compared alirocumab with placebo in 18 924 patients with recent acute coronary syndrome receiving intensive or maximum-tolerated statin treatment. METHODS: Patients on alirocumab were classified in prespecified strata of LDL-C achieved at 4 months of treatment: <25 (n=3357), 25 to 50 (n=3692), or >50 mg/dL (n=2197). For each stratum, MACE (coronary heart disease death, nonfatal myocardial infarction, ischemic stroke, or hospitalization for unstable angina) after month 4 was compared in patients receiving placebo with similar baseline characteristics and adherence by using 1:1 propensity score matching. RESULTS: Across achieved LDL-C strata of the alirocumab group, patients differed by baseline LDL-C, lipoprotein(a), use of intensive statin therapy, study medication adherence, and other demographic, medical history, biometric, and laboratory criteria. After propensity score matching, characteristics were similar in corresponding patients of the alirocumab and placebo groups. Treatment hazard ratio, 95% CI, and absolute risk reduction (number per 100 patient-years) for MACE were similar in those with achieved LDL-C <25 mg/dL (hazard ratio, 0.74 [95% CI, 0.62-0.89]; absolute risk reduction, 0.92) or 25 to 50 mg/dL (hazard ratio, 0.74 [95% CI, 0.64-0.87]; absolute risk reduction, 1.05). Patients with achieved LDL-C >50 mg/dL had poorer adherence and derived less benefit (hazard ratio, 0.87 [95% CI, 0.73-1.04]; absolute risk reduction, 0.62). No safety concerns were associated with a limited period of LDL-C levels <15 mg/dL. CONCLUSIONS: After accounting for differences in baseline characteristics and adherence, patients treated with alirocumab who achieved LDL-C levels <25 mg/dL had a reduction in the risk of MACE that was similar to that of patients who achieved LDL-C levels of 25 to 50 mg/dL. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01663402.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Schwartz GG, Gabriel Steg P, Bhatt DL, et al. Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial. Circulation. 2021. PMID: 33438437. doi:10.1161/CIRCULATIONAHA.120.049447

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。